Surmodics (NASDAQ:SRDX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Surmodics (NASDAQ:SRDX) in a research report sent to investors on Sunday. The firm issued a hold rating on the stock.

Several other research firms also recently issued reports on SRDX. Lake Street Capital reissued a hold rating and issued a $43.00 target price on shares of Surmodics in a research report on Wednesday, May 29th. Sidoti reissued a neutral rating and set a $43.00 target price on shares of Surmodics in a report on Wednesday, May 29th. Barrington Research restated a market perform rating on shares of Surmodics in a research note on Thursday, May 30th. Finally, Needham & Company LLC reissued a hold rating on shares of Surmodics in a report on Monday, August 5th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company has an average rating of Hold and a consensus price target of $50.00.

Surmodics Stock Down 2.5 %

SRDX stock opened at $40.02 on Friday. The stock has a market capitalization of $571.09 million, a PE ratio of 42.13 and a beta of 1.18. Surmodics has a 52 week low of $25.17 and a 52 week high of $42.44. The company has a quick ratio of 3.22, a current ratio of 3.98 and a debt-to-equity ratio of 0.25. The firm has a 50 day moving average of $41.74 and a 200 day moving average of $34.85.

Hedge Funds Weigh In On Surmodics

A number of large investors have recently added to or reduced their stakes in SRDX. SG Americas Securities LLC lifted its stake in shares of Surmodics by 14.7% in the first quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock worth $151,000 after buying an additional 660 shares in the last quarter. Hillsdale Investment Management Inc. increased its position in shares of Surmodics by 15.7% during the fourth quarter. Hillsdale Investment Management Inc. now owns 4,570 shares of the company’s stock valued at $166,000 after acquiring an additional 620 shares during the last quarter. Lazard Asset Management LLC increased its holdings in Surmodics by 13.4% in the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock valued at $166,000 after purchasing an additional 673 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Surmodics by 7.5% during the first quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock worth $202,000 after purchasing an additional 481 shares in the last quarter. Finally, Hardin Capital Partners LLC purchased a new position in Surmodics during the 2nd quarter valued at about $206,000. 96.63% of the stock is currently owned by institutional investors and hedge funds.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).